DermTech Appoints Mark Aguillard as Chief Commercial Officer
11 Septiembre 2023 - 7:05AM
Business Wire
DermTech, Inc. (NASDAQ: DMTK) (DermTech or the Company), a
leader in precision dermatology enabled by a non-invasive skin
genomics technology, today announced the appointment of Mark
Aguillard as chief commercial officer effective September 19, 2023.
Mr. Aguillard will lead DermTech’s overall commercial strategy and
execution.
Commenting on Mr. Aguillard’s appointment, Bret Christensen,
DermTech’s CEO said, “I’d like to welcome Mark to the team. We are
confident that his demonstrated success and wide breadth of
commercial and payer access experience will serve us well during
this transformational period as we focus on generating reimbursed
tests to grow revenue. Mark’s leadership will be important as we
strive to integrate the DermTech Melanoma Test (DMT) into the
melanoma care pathway.”
Mr. Aguillard said, “I’m excited to be leading the
commercialization efforts for the DMT. Patient access is critical
as we deploy our technology to evaluate suspicious pigmented
lesions and potentially save lives. I’m impressed by DermTech’s
accomplishments and I look forward to partnering with the team to
accelerate revenue growth and scale the business to reach more
patients.”
Mr. Aguillard is a proven commercial leader with over 20 years
of experience driving growth through the development and
commercialization of multiple, novel molecular diagnostics. Prior
to joining the Company, he served as the chief commercial officer
of Epic Sciences, where he led the development and launch of a
novel liquid biopsy, DefineMBC, designed to personalize treatment
for patients with metastatic breast cancer. Prior to joining Epic,
Mr. Aguillard served in commercial leadership roles with Myriad
Genetics, binx health, OmniSeq and Eli Lilly & Company
directing sales, marketing, medical affairs, customer success and
market access teams across oncology and women’s health. Mr.
Aguillard received his Bachelor’s in Business Administration with a
major in Finance from Texas Tech University.
About DermTech
DermTech is a leading genomics company in dermatology and is
creating a new category of medicine, precision dermatology, enabled
by its non-invasive skin genomics technology. DermTech’s mission is
to improve the lives of millions by providing non-invasive
precision dermatology solutions that enable individualized care.
DermTech provides genomic analysis of skin samples collected
non-invasively using our Smart Stickers™. DermTech develops and
markets products that facilitate the assessment of melanoma. For
additional information, please visit DermTech.
Forward-Looking Statements
This press release includes “forward-looking statements” within
the meaning of the “safe harbor” provisions of the Private
Securities Litigation Reform Act of 1995. The expectations,
estimates, and projections of DermTech may differ from its actual
results and consequently, you should not rely on these
forward-looking statements as predictions of future events. Words
such as “expect,” “estimate,” “project,” “budget,” “forecast,”
"outlook," “anticipate,” “intend,” “plan,” “strive," “may,” “will,”
“could,” “should,” “believe,” “predict,” “potential,” “continue,”
and similar expressions are intended to identify such
forward-looking statements. These forward-looking statements
include, without limitation, expectations and evaluations with
respect to: the performance, patient benefits, cost- effectiveness,
commercialization and adoption of DermTech’s products and the
market opportunity for these products; expectations regarding
DermTech’s potential growth, scale, patient reach, financial
outlook and future financial performance DermTech’s ability to
increase its test volume, revenue and the proportion of reimbursed
billable tests; and expectations regarding agreements with or
reimbursement or cash collection patterns from government payers
(including Medicare) or commercial payers and related billing
practices or number of covered lives. These forward-looking
statements involve significant risks and uncertainties that could
cause the actual results to differ materially from the expected
results. Most of these factors are outside of the control of
DermTech and are difficult to predict. Factors that may cause such
differences include, but are not limited to: (1) the outcome of any
legal proceedings that may be instituted against DermTech; (2)
DermTech’s ability to obtain additional funding to develop and
market its products; (3) the existence of favorable or unfavorable
clinical guidelines for DermTech’s tests; (4) the reimbursement of
DermTech’s tests by government payers (including Medicare) and
commercial payers; (5) the ability of patients or healthcare
providers to obtain coverage of or sufficient reimbursement for
DermTech’s products; (6) DermTech’s ability to grow, manage growth
and retain its key employees and maintain or improve its operating
efficiency and reduce operating expenses; (7) changes in applicable
laws or regulations; (8) the market adoption and demand for
DermTech’s products and services together with the possibility that
DermTech may be adversely affected by other economic, business,
and/or competitive factors; and (9) other risks and uncertainties
included in the “Risk Factors” section of the most recent Annual
Report on Form 10-K filed by DermTech with the Securities and
Exchange Commission (the “SEC”), and other documents filed or to be
filed by DermTech with the SEC, including subsequently filed
reports. DermTech cautions that the foregoing list of factors is
not exclusive. You should not place undue reliance upon any
forward- looking statements, which speak only as of the date made.
DermTech does not undertake or accept any obligation or undertaking
to release publicly any updates or revisions to any forward-looking
statements to reflect any change in its expectations or any change
in events, conditions, or circumstances on which any such statement
is based.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230911478794/en/
Steve Kunszabo DermTech (858) 291-1647
steve.kunszabo@dermtech.com
DermTech (NASDAQ:DMTK)
Gráfica de Acción Histórica
De Abr 2024 a May 2024
DermTech (NASDAQ:DMTK)
Gráfica de Acción Histórica
De May 2023 a May 2024